Good Life Advisors LLC Invests $217,000 in Danaher Co. (NYSE:DHR)

Good Life Advisors LLC acquired a new stake in Danaher Co. (NYSE:DHR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 779 shares of the conglomerate’s stock, valued at approximately $217,000.

Other institutional investors have also bought and sold shares of the company. Tsfg LLC boosted its position in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Danaher during the 1st quarter worth approximately $30,000. Finally, MFA Wealth Advisors LLC bought a new position in Danaher in the 2nd quarter worth approximately $51,000. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on DHR shares. Barclays raised their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Stephens assumed coverage on shares of Danaher in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price on the stock. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Leerink Partners lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Bank of America lifted their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.9 %

Shares of DHR stock opened at $274.38 on Monday. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $270.72 and its 200 day moving average is $260.13. The stock has a market capitalization of $203.23 billion, a P/E ratio of 46.51, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the firm earned $2.05 earnings per share. The company’s quarterly revenue was down 2.9% on a year-over-year basis. Research analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s payout ratio is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.